Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ana Boban & Cedric Hermans. (2020) An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A. Expert Review of Hematology 13:4, pages 303-311.
Read now
Read now
Kenneth Lieuw. (2017) Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?. Journal of Blood Medicine 8, pages 67-73.
Read now
Read now
Kamilla Swiech, Virgínia Picanço-Castro & Dimas Tadeu Covas. (2017) Production of recombinant coagulation factors: Are humans the best host cells?. Bioengineered 8:5, pages 462-470.
Read now
Read now
Christoph Kannicht, Guido Kohla, Maya Tiemeyer, Olaf Walter & Helena Sandberg. (2015) A new recombinant factor VIII: from genetics to clinical use. Drug Design, Development and Therapy 9, pages 3817-3819.
Read now
Read now
Articles from other publishers (8)
Kunal Kerkar, Manisha Tiwari, Dhermendra K. Tiwari & Savita Kerkar. 2021. Microbial Products for Health, Environment and Agriculture. Microbial Products for Health, Environment and Agriculture
183
202
.
M. Joseph John, Prantar Chakrabarti, Shashikant Apte, Maitreyee Bhattacharyya, Chandrakala S.Trine Hansen, Rohan Kolla, Cecil Ross, Tulika Seth, Neeraj Siddharthan & Aby Abraham. (2020) Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results. Research and Practice in Thrombosis and Haemostasis 4:8, pages 1324-1330.
Crossref
Crossref
Toshko Lissitchkov, Anna Klukowska, John Pasi, Craig M. Kessler, Robert Klamroth, Raina J. Liesner, Larisa Belyanskaya, Olaf Walter, Sigurd Knaub, Johann Bichler, Martina Jansen & Johannes Oldenburg. (2019) Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Therapeutic Advances in Hematology 10, pages 204062071985847.
Crossref
Crossref
D. Baunsgaard, A. D. Nielsen, P. F. Nielsen, A. Henriksen, A. K. Kristensen, H. W. Bagger & M. Ezban. (2018) A comparative analysis of heterogeneity in commercially available recombinant factor VIII products. Haemophilia 24:6, pages 880-887.
Crossref
Crossref
Masahiro Takeyama, Keiji Nogami, Ryohei Kobayashi, Kenichi Ogiwara, Akira Taniguchi, Yasuaki Nakanishi, Yusuke Inagaki, Yasuhito Tanaka & Midori Shima. (2018) Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report. International Journal of Hematology 108:2, pages 199-202.
Crossref
Crossref
Vladimir Granovski, Mario Soares Abreu-Neto & Dimas Tadeu Covas. 2018. Recombinant Glycoprotein Production. Recombinant Glycoprotein Production
195
202
.
N. Shurko, T. Danysh & V. Novak. (2017) THE COAGULATION FACTOR VIII: STRUCTURE AND APPLICATION. Visnyk of Lviv University. Biological series:76, pages 184-192.
Crossref
Crossref
Charles L. Groomes, David M. Gianferante, Gary D. Crouch, Dina S. Parekh, David W. Scott & Kenneth Lieuw. (2016) Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein. Pediatric Blood & Cancer 63:5, pages 922-924.
Crossref
Crossref